Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Crispr Therapeutics Ag
(NQ:
CRSP
)
55.65
-0.76 (-1.35%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Crispr Therapeutics Ag
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
26
27
Next >
7 Biotech Stocks to Get In Now Before Investors Catch On
October 23, 2023
Biotech stocks are down, but there are hidden gems among the rubble. Get in now before the broader market finds them.
Via
InvestorPlace
CRISPR Therapeutics Stock: Bull vs. Bear
October 21, 2023
Here's the scoop on one of the most widely followed gene-editing stocks on the market.
Via
The Motley Fool
Cathie Wood Is Buying These Top Growth Stocks -- and Both Could Make You Richer Over Time
October 21, 2023
Wood is going all in on gene editing.
Via
The Motley Fool
3 Gene Editing Stocks to Generate Super-Charged Gains
October 18, 2023
As things progress, such techniques may be able to knock out every disease known, creating massive opportunity for gene-editing stocks.
Via
InvestorPlace
Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing
October 18, 2023
The company can begin a pivotal study of its treatment for cardiomyopathy.
Via
Investor's Business Daily
Cathie Wood-Led Ark Invest Sells Over $6.5M Worth Of Tesla Stock, What's Going On?
October 17, 2023
Via
Benzinga
Cautious Optimism For Bluebird Bio's Sickle Cell Therapy: Analyst Sees Financial Challenges
October 17, 2023
Cantor Fitzgerald initiated coverage on Bluebird Bio Inc (NASDAQ: BLUE), saying sickle cell disorder (SCD) has been a hotbed of development for genetic medicines as the company's lovo-cel marches...
Via
Benzinga
Editas Medicine Has To Navigate Sickle Cell Therapy Competition: Analyst
October 17, 2023
Cantor Fitzgerald has downgraded Editas Medicine Inc (NASDAQ: EDIT) to Neutral from Overw
Via
Benzinga
Mixed Signals For CRISPR Therapeutics, Analyst Weighs Barriers, Potential Sales For Sickle Cell Therapy
October 17, 2023
Cantor Fitzgerald has downgraded CRISPR Therapeutics AG (NASDAQ: CRSP) to Neutral from Ov
Via
Benzinga
This Cathie Wood Stock Is Set to Soar 100%, Says Wall Street
October 16, 2023
This Wood favorite is heading for a big moment.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023
October 17, 2023
Via
Benzinga
2 Growth Stocks That Could Double Your Money, According to Wall Street
October 15, 2023
Find out why investment bank analysts are pounding the table on these stocks.
Via
The Motley Fool
2 Growth Stocks That Could Deliver Parabolic Returns in Under 5 Years
October 14, 2023
These two gene-editing stocks could be diamonds in the rough.
Via
The Motley Fool
Cathie Wood's Ark Invest Sells $9.8M Worth Of Tesla Shares — Second Day Of Selling EV Giant In A Row
October 11, 2023
Via
Benzinga
Cathie Wood's Ark Invest Keeps On Cutting Tesla Holdings, Sells More Than $8M Worth Of EV Maker's Shares
October 10, 2023
Via
Benzinga
Cathie Wood Is Buying CRISPR Therapeutics Ahead of This Big Event. Should You?
October 10, 2023
Wood has outperformed the market so far this year.
Via
The Motley Fool
Cathie Wood Goes Shopping For Stock of Jack Dorsey's Block — Ark Invest Bolsters Portfolio With Archer Aviation, CRISPR Shares
October 09, 2023
Via
Benzinga
3 No-Brainer Growth Stocks to Buy in October
October 07, 2023
The time is right to invest in these great stocks.
Via
The Motley Fool
2 Growth Stocks That Can Rocket 98% to 108% Higher, According to Wall Street
October 05, 2023
The analysts who follow these stocks have some big expectations for the year ahead.
Via
The Motley Fool
Cathie Wood's Ark Invest Sells Over $25M Worth Of Tesla Shares Amid Boost In Price
October 04, 2023
Via
Benzinga
Biotechnology Breakthroughs: 3 Biotech Stocks That Could Make Early Investors Rich
October 03, 2023
Are you looking to invest in biotechnology breakthroughs? Here are three biotech stocks that could make early investors rich.
Via
InvestorPlace
Cathie Wood Is Buying This Growth Stock Hand Over Fist Lately. Should You Follow Her Lead?
October 03, 2023
The Internet's most famous innovation-focused investor is excited about this company's innovative approach to editing the human genome.
Via
The Motley Fool
2 Top Biotech Stocks to Buy in October
October 03, 2023
Growth catalysts lie ahead for both of these players.
Via
The Motley Fool
Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics
October 02, 2023
The better of the pair should be able to beat Bluebird Bio.
Via
The Motley Fool
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
October 01, 2023
These companies are helping change medicine; they could make boatloads of money along the way.
Via
The Motley Fool
3 Cathie Wood Stocks Set to Explode Higher
October 01, 2023
Delve into the exciting world of Cathie Wood Stocks where potential meets performance, offering investors hefty long-term upside.
Via
InvestorPlace
Futurescape: Betting Big on These 3 Next-Gen Tech Stocks
October 01, 2023
These next-gen tech stocks that emphasize forward-thinking innovation are perfect for investors who seek big bets or massive gains.
Via
InvestorPlace
3 No-Brainer Growth Stocks to Buy in October
October 01, 2023
These three top mid-cap stocks could be poised for a long-tailed growth spurt.
Via
The Motley Fool
Editas Medicine Is Beyond Skepticism, Analyst Has Confidence In Sickle Cell Therapy, Upgrades Stock
September 29, 2023
Stifel has upgraded Editas Medicine Inc (NASDAQ: EDIT), saying the company's sickle cell disease candidate, EDIT-301's progress, has received minimal credit from investors.
Via
Benzinga
Why Editas Medicine Stock Is Soaring Today
September 29, 2023
Investors are cheering a big analyst upgrade for the gene-editing stock.
Via
The Motley Fool
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
26
27
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.